Fig. 1From: Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor–related protein agonist AMG 228 in patients with advanced solid tumorsMean (± SD) pharmacokinetic profile of AMG 228 following intravenous administration of AMG 228 every 3 weeks. Blood samples were collected predose, at the end of infusion, and postdose over the 3-week dosing interval during treatment cyclesBack to article page